Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome
jRCT2080222300Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vatiquinone in Leigh syndrome, sponsored by Sumitomo Pharma.
02
Drugs
vatiquinone
03
Conditions
Leigh syndrome
Beyond the preview
Go deeper on jRCT2080222300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222300.